Centessa Pharmaceuticals (CNTA) EBITDA Margin (2025)
Centessa Pharmaceuticals (CNTA) reported EBITDA Margin of 188.49% for Q1 2025.
Centessa Pharmaceuticals (CNTA) has 1 years of EBITDA Margin data on file, last reported at 188.49% in Q1 2025.
- Quarterly EBITDA Margin changed N/A year-over-year to 188.49% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 1326.87% (changed N/A YoY) and the FY2025 annual result came in at 1326.87%, changed N/A from the prior year.
- EBITDA Margin steadied at 188.49% in Q1 2025 per CNTA's latest filing.
- Across five years, EBITDA Margin topped out at 188.49% in Q1 2025 and bottomed at 188.49% in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.24% |
| 10 | Centessa Pharmaceuticals | 6.12 Bn | 6.12 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -188.49% |